Evidence map›Paper›PMID 15367677›Full record

ArticleMolecular and cellular biology2004

FANCG is phosphorylated at serines 383 and 387 during mitosis.

Jun Mi, Fengyu Qiao, James B Wilson, Anthony A High, Melanie J Schroeder, Peter T Stukenberg, Amy Moss, Jeffrey Shabanowitz, Donald F Hunt, Nigel J Jones and 1 more

Open access · greenAbstract read
In one paragraph

Article in Molecular and cellular biology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 38 citations in OpenAlex.

  1. Review
  2. Cellular response to DNA interstrand crosslinks: the Fanconi anemia pathway.Cellular and molecular life sciences : CMLS · 2016
    Review
  3. Article
  4. Review
  5. Fanconi anemia: a signal transduction and DNA repair pathway.The Yale journal of biology and medicine · 2013
    Review
  6. Article
  7. Article
  8. Review
  9. The Fanconi anemia pathway and ICL repair: implications for cancer therapy.Critical reviews in biochemistry and molecular biology · 2010
    Review
  10. Article
  11. Article
  12. Review
  13. Fanconi anemia.Hematology/oncology clinics of North America · 2009
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Molecular pathogenesis of Fanconi anemia.International journal of hematology · 2005
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Jun MiDepartment of Microbiology, University of Virginia Health System, Charlottesville, VA, USA.
Fengyu Qiao
James B Wilson
Anthony A High
Melanie J Schroeder
Peter T Stukenberg
Amy Moss
Jeffrey Shabanowitz
Donald F Hunt
Nigel J Jones
Gary M Kupfer
University of Virginia · USUniversity of Liverpool · GBPediatrics and Genetics · USUniversity of Virginia Health System · US

Funding

PROTEIN SEQUENCING BY TANDEM MASS SPECTROMETRYR01GM037537 · NIGMS · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI HUNT, DONALD F · 1987 to 2023
$17.8M
NIGMS NIH HHS GM37537NIGMS NIH HHS R01 GM037537
6 · The paper itself

Abstract

Fanconi anemia (FA) is an autosomal recessive disease marked by congenital defects, bone marrow failure, and high incidence of leukemia and solid tumors. Eight genes have been cloned, with the accompanying protein products participating in at least two complexes, which appear to be functionally dependent upon one another. Previous studies have described chromatin localization of the FA core complex, except at mitosis, which is associated with phosphorylation of the FANCG protein (F. Qiao, A. Moss, and G. M. Kupfer, J. Biol. Chem. 276:23391-23396, 2001). The phosphorylation of FANCG at serine 7 by using mass spectrometry was previously mapped. The purpose of this study was to map the phosphorylation sites of FANCG at mitosis and to assess their functional importance. Reasoning that a potential kinase might be cdc2, which was previously reported to bind to FANCC, we showed that cdc2 chiefly phosphorylated a 14-kDa fragment of the C-terminal half of FANCG. Mass spectrometry analysis demonstrated that this fragment contains amino acids 374 to 504. Kinase motif analysis demonstrated that three amino acids in this fragment were leading candidates for phosphorylation. By using PCR-directed in vitro mutagenesis we mutated S383, S387, and T487 to alanine. Mutation of S383 and S387 abolished the phosphorylation of FANCG at mitosis. These results were confirmed by use of phosphospecific antibodies directed against phosphoserine 383 and phosphoserine 387. Furthermore, the ability to correct FA-G mutant cells of human or hamster (where S383 and S387 are conserved) origin was also impaired by these mutations, demonstrating the functional importance of these amino acids. S387A mutant abolished FANCG fusion protein phosphorylation by cdc2. The FA pathway, of which FANCG is a part, is highly regulated by a series of phosphorylation steps that are important to its overall function.

Indexed as

AnimalsCDC2 Protein KinaseCHO CellsCricetinaeDNA-Binding ProteinsFanconi Anemia Complementation Group G ProteinHeLa CellsHumansMass SpectrometryMitosisMutationPhosphorylationSerineCDC2 Protein KinaseDNA-Binding ProteinsFANCG protein, humanFanconi Anemia Complementation Group G ProteinSerine

Identifiers

PMID15367677
PMCPMC516759
OpenAlexW2172034068

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.